AI
AstraZeneca signs AI research deal with China’s CSPC for chronic diseases
[ad_1]
AstraZeneca has signed an AI-led research agreement with China’s CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic conditions, it said on Friday.
The deal marks the latest effort by AstraZeneca to revive its business in China, its second-biggest market, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports.
Under Friday’s agreement, the two companies will collaborate to discover and develop…
[ad_2]
Source link
Continue Reading
You must be logged in to post a comment Login